A PIPELINE POWERED BYPASSION
PUBLICATIONS AND PRESENTATIONS
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure
JAMA Cardiology
Felker GM, Solomon SD, Claggett B, et al
October 13, 2021
Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function
Journal of Medicinal Chemistry
Collibee SE, Bergnes G, Chuang C, Ashcraft L, Gardina J, Garard M, Jamison CR, Lu K, Lu P, et al.
October 12, 2021
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
Journal of Medicinal Chemistry
Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER, Cremin P, Zamora J, Hartman J, Schaletzy J, Wehri E, Robertson LA, Malik FI, Morgan BP
October 4, 2021
REDWOOD-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, Aficamten, In Obstructive Hypertrophic Cardiomyopathy
Presentation, Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Maron, M, et al
Denver, CO
September 12, 2021
Effect of Omecamtiv Mecarbil in Black Patients with Heart Failure and Reduced Ejection Fraction
Presentation, Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Lanfear, DE, et al
Denver, CO
September 12, 2021